Global investment firm Carlyle group on Wednesday exited Indegene by divesting its entire 10.2 per cent stake in digital healthcare services for Rs 1,447 crore through open market transactions.

The healthcare tech firm's stock fell as much as 4.68 per cent during the day to ₹590 per share, the biggest intraday loss since April 5 this year. The stock pared losses to trade 4.4 per cent lower ...

Shares of Indegene Ltd. fell over 4% on Wednesday as US private equity firm Carlyle Group is looking to exit by selling ...

With this deal, Carlyle has made a complete exit from Indegene. At the end of the March quarter, CA Dawn Investments had a 10.2% stake in the company.

PRINCETON, N.J. and BENGALURU, India, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, today announced that it is helping AstraZeneca ...

Life-sci commercialization company Indegene has filed for an initial public offering with India’s securities and exchange board (SEBI), as private equity backers The Carlyle Group and Brighton Park ...

To that end, life-sci commercialization firm Indegene formally launched a new tool that harnesses physician-level data and other insights to aid biopharma companies in personalizing campaigns Tuesday ...

Life sciences commercialization supporter Indegene is beefing up its drug marketing capabilities through an acquisition. Bangalore-based Indegene will acquire CultHealth, a full-service healthcare ...

Indegene has officially launched Invisage, its new sales and marketing program. Aimed at helping life science companies optimize their go-to-market models, the technology reportedly delivers ...

Indegene has struck a deal with two investment companies that will see them take a $200 million minority stake in the healthtech company. The funding from The Carlyle Group and Brighton Park ...

According to a report by GlobeNewswire, Cingulate Inc., a biopharmaceutical company, and Indegene, a life sciences commercialization organization, are collaborating on the biopharmaceutical’s lead ...